The American Cancer Society report also found rapid declines in melanoma death rates, up to 7 percent a year from 2013 to 2017 among adults, also attributable to new treatments.
In 2011, the Food and Drug Administration approved two key drugs to treat melanoma: ipilimumab and vemurafenib. "We're actually seeing the effect of those drugs reflected in the overall melanoma death rate," said Rebecca Siegel, scientific director of surveillance research at the American Cancer Society and an author of the new report."That's really exciting.""In the past decade, how we treat invasive melanoma has evolved so unbelievably rapidly that it is, for some, becoming more of a chronic disease than a death sentence," said Dr.
Doesn’t count cancer that has spread dontignorestage4